Cost-utility analysis of telitacicept versus belimumab in the treatment of systemic lupus erythematosus in China
Under current pricing, treatment settings and efficacy data in China, telitacicept demonstrates superior cost-effectiveness compared with belimumab for long-term SLE management by reducing medication costs while delivering additional health benefits.
Authors
- Chaoying Liu (ORCID: https://orcid.org/0000-0003-0484-9522)
- Fangxu Wang
- Yi Yan (ORCID: https://orcid.org/0000-0002-4993-7764)
- Su Sun
- Lei Tao
- Yao Wu (ORCID: https://orcid.org/0000-0002-3920-1518)
Institutions
- Peking University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2026-01-15
- DOI
- https://doi.org/10.3389/fpubh.2025.1712454
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00